What Is Angioimmunoblastic T-Cell Lymphoma?

A diagnosis of angioimmunoblastic T-cell lymphoma, commonly called AITL, can be a lot to process — starting with the name. Understanding what AITL is, how it is staged and what treatment looks like can help people feel more prepared as they begin working with their care team.

What Is Angioimmunoblastic T-Cell Lymphoma?

AITL is a rare, fast-growing blood cancer that develops in T cells, a type of white blood cell that normally helps the body fight infection. When these cells become abnormal and multiply out of control, they can build up in the lymph nodes and spread elsewhere. AITL falls under the broader category of non-Hodgkin lymphoma and most commonly affects older adults, though it can occur at any age.

Because its symptoms — swollen lymph nodes, fever, night sweats, skin rash, unexplained weight loss and fatigue — closely resemble those of infections and autoimmune conditions, AITL is often caught late. Diagnosis typically requires a lymph node biopsy along with imaging such as CT or PET scans and sometimes a bone marrow biopsy.

The Stages of Angioimmunoblastic T-Cell Lymphoma

AITL is staged using the Ann Arbor staging system. In stage I, the cancer is confined to a single lymph node region. In stage II, it has spread to nearby lymph nodes but remains on one side of the diaphragm — the muscle separating the chest from the abdomen. Stages I and II are considered early-stage and are uncommon in AITL.

Stage III means lymph nodes on both sides of the diaphragm are involved. Stage IV means the cancer has spread into organs such as the liver, bone marrow or skin. Both are considered advanced-stage disease, and most people with AITL are diagnosed at one of these stages.

Treatment Options for Angioimmunoblastic T-Cell Lymphoma

Because AITL grows quickly, treatment usually begins soon after diagnosis. For early-stage disease, combination chemotherapy is the standard approach and may be paired with radiation to involved areas.

For advanced-stage disease, the most widely used regimen is CHOP — a combination of Cytoxan (cyclophosphamide), doxorubicin (hydroxydaunorubicin), Oncovin (vincristine sulfate) and prednisone. Another option, BV+CHP, incorporates Adcetris (brentuximab vedotin) and is used in certain cases. Steroids are sometimes added early to ease immune-related symptoms like joint pain or rash.

For people whose disease responds to chemotherapy, a stem cell transplant — using either the person's own stem cells or a donor's — may follow to reduce the risk of recurrence. Targeted therapies that act on the genetic changes driving the cancer are also used, particularly in relapsed disease. Clinical trial participation is often encouraged given how rare AITL is and how actively new treatments are being studied.

Side Effects and Survivorship

Chemotherapy commonly causes fatigue, nausea, hair loss and lowered blood cell counts, which can raise infection risk. Steroids may bring mood changes, fluid retention and disrupted sleep. Stem cell transplant recipients face additional considerations including a period of immune suppression and, in some cases, graft-versus-host disease.

Recovery after treatment takes time. Fatigue, difficulty concentrating and heightened infection sensitivity are common in the months that follow. Emotional wellbeing matters just as much — anxiety about recurrence and adjusting to life after treatment are real challenges that support groups and mental health professionals can help address. Regular follow-up appointments, imaging and blood work remain important long after treatment ends.

References

1. "Angioimmunoblastic T-Cell Lymphoma." Lymphoma Research Foundation, lymphoma.org.
2. "Angioimmunoblastic T-Cell Lymphoma (AITL)." Cleveland Clinic, my.clevelandclinic.org.
3. "Angioimmunoblastic T-Cell Lymphoma: The Many-Faced Lymphoma" by Dr. Lunning, et al., Blood.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.